NBTXR3

About Nanobiotix

Nanobiotix is a French biotechnology company developing novel nanotherapeutics that aim to revolutionize cancer treatment by enhancing the efficacy of radiotherapy. Its core technology involves hafnium oxide nanoparticles (NBTXR3) that, when activated by radiotherapy, produce a significant increase in tumor cell death and may stimulate an adaptive immune response. The company has achieved key milestones with positive Phase 3 results in soft tissue sarcoma and is advancing clinical programs across multiple solid tumor indications, supported by strategic partnerships with global leaders like Johnson & Johnson and LianBio.

About Nanobiotix

Nanobiotix is a French biotechnology company developing novel nanotherapeutics that aim to revolutionize cancer treatment by enhancing the efficacy of radiotherapy. Its core technology involves hafnium oxide nanoparticles (NBTXR3) that, when activated by radiotherapy, produce a significant increase in tumor cell death and may stimulate an adaptive immune response. The company has achieved key milestones with positive Phase 3 results in soft tissue sarcoma and is advancing clinical programs across multiple solid tumor indications, supported by strategic partnerships with global leaders like Johnson & Johnson and LianBio.

About Nanobiotix

Nanobiotix is a French biotechnology company developing novel nanotherapeutics that aim to revolutionize cancer treatment by enhancing the efficacy of radiotherapy. Its core technology involves hafnium oxide nanoparticles (NBTXR3) that, when activated by radiotherapy, produce a significant increase in tumor cell death and may stimulate an adaptive immune response. The company has achieved key milestones with positive Phase 3 results in soft tissue sarcoma and is advancing clinical programs across multiple solid tumor indications, supported by strategic partnerships with global leaders like Johnson & Johnson and LianBio.

About Nanobiotix

Nanobiotix is a French biotechnology company developing novel nanotherapeutics that aim to revolutionize cancer treatment by enhancing the efficacy of radiotherapy. Its core technology involves hafnium oxide nanoparticles (NBTXR3) that, when activated by radiotherapy, produce a significant increase in tumor cell death and may stimulate an adaptive immune response. The company has achieved key milestones with positive Phase 3 results in soft tissue sarcoma and is advancing clinical programs across multiple solid tumor indications, supported by strategic partnerships with global leaders like Johnson & Johnson and LianBio.

About Nanobiotix

Nanobiotix is a French biotechnology company developing novel nanotherapeutics that aim to revolutionize cancer treatment by enhancing the efficacy of radiotherapy. Its core technology involves hafnium oxide nanoparticles (NBTXR3) that, when activated by radiotherapy, produce a significant increase in tumor cell death and may stimulate an adaptive immune response. The company has achieved key milestones with positive Phase 3 results in soft tissue sarcoma and is advancing clinical programs across multiple solid tumor indications, supported by strategic partnerships with global leaders like Johnson & Johnson and LianBio.

About LianBio

LianBio operates as a strategic bridge, connecting innovative global biopharmaceutical assets with high-growth Asian markets, particularly China. The company leverages its deep regional expertise in development, regulatory affairs, and commercialization to advance a portfolio of clinical-stage and commercial-stage therapies. Its business model mitigates early-stage R&D risk by focusing on de-risked, externally sourced candidates with proof-of-concept data. A key strategic move was the announcement in late 2023 to wind down operations and return capital to shareholders, following a review of its strategic alternatives.

Therapeutic Areas